AR041713A1 - Una composicoin farmaceutica de duracion prolongada - Google Patents
Una composicoin farmaceutica de duracion prolongadaInfo
- Publication number
- AR041713A1 AR041713A1 ARP030103884A ARP030103884A AR041713A1 AR 041713 A1 AR041713 A1 AR 041713A1 AR P030103884 A ARP030103884 A AR P030103884A AR P030103884 A ARP030103884 A AR P030103884A AR 041713 A1 AR041713 A1 AR 041713A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical
- composicoin
- prolonged duration
- prolonged
- duration
- Prior art date
Links
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 229940083916 aluminum distearate Drugs 0.000 abstract 1
- RDIVANOKKPKCTO-UHFFFAOYSA-K aluminum;octadecanoate;hydroxide Chemical compound [OH-].[Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O RDIVANOKKPKCTO-UHFFFAOYSA-K 0.000 abstract 1
- 229950009592 cefquinome Drugs 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02079477 | 2002-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041713A1 true AR041713A1 (es) | 2005-05-26 |
Family
ID=32116298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103884A AR041713A1 (es) | 2002-10-25 | 2003-10-24 | Una composicoin farmaceutica de duracion prolongada |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1558263B1 (enExample) |
| JP (1) | JP4584715B2 (enExample) |
| CN (1) | CN1326526C (enExample) |
| AR (1) | AR041713A1 (enExample) |
| AT (1) | ATE327759T1 (enExample) |
| AU (1) | AU2003279302B2 (enExample) |
| BR (2) | BRPI0315513B1 (enExample) |
| CA (1) | CA2501395C (enExample) |
| CO (1) | CO5700769A2 (enExample) |
| DE (1) | DE60305728T2 (enExample) |
| ES (1) | ES2265590T3 (enExample) |
| MX (1) | MXPA05004219A (enExample) |
| NO (1) | NO334158B1 (enExample) |
| NZ (1) | NZ539478A (enExample) |
| PL (1) | PL208585B1 (enExample) |
| PT (1) | PT1558263E (enExample) |
| WO (1) | WO2004037265A1 (enExample) |
| ZA (1) | ZA200502956B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007291308A1 (en) * | 2006-08-30 | 2008-03-06 | Intervet International B.V. | Pharmaceutical compositions comprising cefquinome |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤 |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| AR077320A1 (es) * | 2009-07-20 | 2011-08-17 | Intervet Int Bv | Metodo para la preparacion de particulas de cefquinoma y formulaciones farmaceuticas que las comprenden. |
| AU2012206621B2 (en) * | 2011-01-12 | 2017-04-27 | Intervet International B.V. | Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions |
| WO2012095438A1 (en) * | 2011-01-12 | 2012-07-19 | Intervet International B.V. | Particles and suspensions of cephalosporin antibiotics |
| CN102319210B (zh) * | 2011-09-29 | 2013-05-01 | 武汉回盛生物科技有限公司 | 一种兽用长效硫酸头孢喹肟注射液及其制备方法 |
| CN104546703B (zh) * | 2013-12-10 | 2017-06-23 | 中国农业科学院饲料研究所 | 一种奶牛泌乳期用硫酸头孢喹肟乳房注入剂及其制备方法 |
| CN104000783B (zh) * | 2014-05-14 | 2017-12-05 | 河南牧翔动物药业有限公司 | 头孢喹肟脂质体 |
| CN104873462B (zh) * | 2014-11-18 | 2017-04-05 | 中国农业科学院饲料研究所 | 一种奶牛干乳期用硫酸头孢喹肟乳房注入剂及其制备方法 |
| CN107157927A (zh) * | 2017-05-31 | 2017-09-15 | 合肥中龙神力动物药业有限公司 | 动物用硫酸头孢喹肟注射液及其制备方法 |
| CN109044970A (zh) * | 2018-11-08 | 2018-12-21 | 遂宁市中通实业集团动物药业有限公司 | 一种硫酸头孢喹肟注射液及其制备方法 |
| CN113209014A (zh) * | 2020-01-21 | 2021-08-06 | 江西邦诚动物药业有限公司 | 长效硫酸头孢喹肟混悬注射液及其制备工艺 |
| CN113952298B (zh) * | 2021-12-08 | 2023-02-17 | 江苏农牧科技职业学院 | 硫酸头孢喹肟纳米混悬液及其制备方法 |
| CN117982413B (zh) * | 2024-04-03 | 2024-06-18 | 山东恒邦中科生物工程有限公司 | 一种硫酸头孢喹肟注射液的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920819A (en) * | 1974-12-02 | 1975-11-18 | Lilly Co Eli | Nonaqueous vehicle for oral pharmaceutical suspensions |
| IE49768B1 (en) * | 1979-05-21 | 1985-12-11 | Leo Pharm Prod Ltd | 6beta-halopenicillanic acid derivatives |
| IE51846B1 (en) * | 1980-11-17 | 1987-04-15 | Leo Pharm Prod Ltd | Pharmaceutical preparation for veterinary use and an appliance containing it |
| GB8531609D0 (en) * | 1985-12-23 | 1986-02-05 | Beecham Group Plc | Compounds |
| JP3022692B2 (ja) * | 1992-10-13 | 2000-03-21 | 三菱マテリアル株式会社 | リーク検査装置 |
| GB9306106D0 (en) * | 1993-03-24 | 1993-05-12 | Norbrook Lab Ltd | Sustained release veterinary composition |
| DE4440141A1 (de) * | 1994-11-10 | 1996-05-15 | Hoechst Ag | Neue kristalline Cephem-Säureadditionssalze und Verfahren zu ihrer Herstellung |
| GB9907916D0 (en) * | 1999-04-07 | 1999-06-02 | Takeda Chemical Industries Ltd | Long-acting antibacterial composition |
| WO2003063877A1 (en) * | 2002-02-01 | 2003-08-07 | Akzo Nobel N.V. | Cefquinome composition for intra-mammary administration in cattle |
-
2003
- 2003-10-20 ES ES03772240T patent/ES2265590T3/es not_active Expired - Lifetime
- 2003-10-20 MX MXPA05004219A patent/MXPA05004219A/es active IP Right Grant
- 2003-10-20 JP JP2004545913A patent/JP4584715B2/ja not_active Expired - Lifetime
- 2003-10-20 BR BRPI0315513-7A patent/BRPI0315513B1/pt unknown
- 2003-10-20 AT AT03772240T patent/ATE327759T1/de not_active IP Right Cessation
- 2003-10-20 DE DE60305728T patent/DE60305728T2/de not_active Expired - Lifetime
- 2003-10-20 NZ NZ539478A patent/NZ539478A/en not_active IP Right Cessation
- 2003-10-20 PT PT03772240T patent/PT1558263E/pt unknown
- 2003-10-20 EP EP03772240A patent/EP1558263B1/en not_active Expired - Lifetime
- 2003-10-20 AU AU2003279302A patent/AU2003279302B2/en not_active Expired
- 2003-10-20 CA CA2501395A patent/CA2501395C/en not_active Expired - Fee Related
- 2003-10-20 WO PCT/EP2003/011644 patent/WO2004037265A1/en not_active Ceased
- 2003-10-20 PL PL376840A patent/PL208585B1/pl unknown
- 2003-10-20 BR BR0315513-7A patent/BR0315513A/pt active IP Right Grant
- 2003-10-20 CN CNB2003801015269A patent/CN1326526C/zh not_active Expired - Lifetime
- 2003-10-24 AR ARP030103884A patent/AR041713A1/es active IP Right Grant
-
2005
- 2005-04-04 NO NO20051654A patent/NO334158B1/no not_active IP Right Cessation
- 2005-05-23 CO CO05049742A patent/CO5700769A2/es not_active Application Discontinuation
-
2006
- 2006-01-25 ZA ZA200502956A patent/ZA200502956B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2501395A1 (en) | 2004-05-06 |
| CN1326526C (zh) | 2007-07-18 |
| DE60305728D1 (de) | 2006-07-06 |
| MXPA05004219A (es) | 2005-06-08 |
| NO334158B1 (no) | 2013-12-23 |
| BR0315513A (pt) | 2005-08-23 |
| ZA200502956B (en) | 2006-03-29 |
| JP4584715B2 (ja) | 2010-11-24 |
| ATE327759T1 (de) | 2006-06-15 |
| NO20051654L (no) | 2005-05-24 |
| ES2265590T3 (es) | 2007-02-16 |
| JP2006510607A (ja) | 2006-03-30 |
| AU2003279302B2 (en) | 2008-10-16 |
| EP1558263A1 (en) | 2005-08-03 |
| CN1705483A (zh) | 2005-12-07 |
| DE60305728T2 (de) | 2006-10-12 |
| NZ539478A (en) | 2006-05-26 |
| EP1558263B1 (en) | 2006-05-31 |
| PL208585B1 (pl) | 2011-05-31 |
| CO5700769A2 (es) | 2006-11-30 |
| BRPI0315513B1 (pt) | 2017-11-28 |
| CA2501395C (en) | 2011-05-24 |
| PT1558263E (pt) | 2006-10-31 |
| WO2004037265A1 (en) | 2004-05-06 |
| AU2003279302A1 (en) | 2004-05-13 |
| PL376840A1 (pl) | 2006-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041713A1 (es) | Una composicoin farmaceutica de duracion prolongada | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| CY1119168T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη | |
| ITRM20020378A1 (it) | Dispositivo iniettore ipodermico attivabile. | |
| EA200401019A1 (ru) | Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества | |
| ES2572454T3 (es) | Tratamiento de enfermedades mediadas por los linfocitos T | |
| EA200400481A1 (ru) | Применение флибансерина для лечения половых расстройств | |
| ECSP003847A (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
| CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
| NO20053076D0 (no) | Farmasoytisk formulering med en uloselig aktiv forbindelse. | |
| DE60327103D1 (de) | Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer | |
| BRPI0311189B8 (pt) | composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso | |
| CY1113959T1 (el) | Χρηση λιποσωματων pvp-ιωδιου για θεραπεια ακμης | |
| EA200200502A1 (ru) | Способ введения ингибитора фосфодиэстеразы 4 | |
| EA200101150A1 (ru) | Раствор прукалоприда для перорального применения | |
| TR200103125T2 (tr) | Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri. | |
| ATE393917T1 (de) | Identifikation von therapeutische verbindungen. | |
| AR046853A1 (es) | Mezclas insecticidas que contienen triflumuron con actividad sinergica | |
| EA200501231A1 (ru) | Применение дипиридамола в комбинации с ацетилсалициловой кислотой и антагонистом ангиотензина ii для предупреждения инсульта | |
| EA200200798A1 (ru) | Кальцилитические соединения | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| EA200501565A1 (ru) | Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса | |
| HRP20050611B1 (hr) | Kombinacijski lijek | |
| UY26218A1 (es) | Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.- | |
| DK1503803T3 (da) | Injicerbar farmaceutisk sammensætning indeholdende ethanol til at behandle diskusprolaps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |